Nikanjam, Mina
Kato, Shumei
Kurzrock, Razelle
Funding for this research was provided by:
National Cancer Institute (P30 CA023100, P30 CA023100)
Article History
Received: 26 May 2022
Accepted: 6 September 2022
First Online: 12 September 2022
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Kato serves as a consultant for Foundation Medicine, NeoGenomics and CureMatch. He receives speaker’s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta and OmniSeq. Dr. Kurzrock has the following disclosure information: Stock and Other Equity Interests (IDbyDNA, CureMatch, Inc., and Soluventis); Consulting or Advisory Role (Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, Soluventis, Pfizer, and Merck); Speaker’s fee (Roche); Research Funding (Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, DeBiopharm, Boerhringer Ingelheim, and OmniSeq [All institutional]); Board Member (CureMatch, Inc., and CureMetrix, Inc.). Dr. Nikanjam own Genentech stock.